Cytokinetics (CYTK) Debt to Equity: 2010-2025
Historic Debt to Equity for Cytokinetics (CYTK) over the last 10 years, with Sep 2025 value amounting to -$0.34.
- Cytokinetics' Debt to Equity rose 95.55% to -$0.34 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.34, marking a year-over-year increase of 95.55%. This contributed to the annual value of -$0.77 for FY2024, which is 336.62% down from last year.
- According to the latest figures from Q3 2025, Cytokinetics' Debt to Equity is -$0.34, which was up 29.50% from -$0.48 recorded in Q2 2025.
- Cytokinetics' 5-year Debt to Equity high stood at $2.84 for Q2 2021, and its period low was -$7.59 during Q3 2024.
- Moreover, its 3-year median value for Debt to Equity was -$0.28 (2023), whereas its average is -$0.87.
- Within the past 5 years, the most significant YoY rise in Cytokinetics' Debt to Equity was 620.68% (2024), while the steepest drop was 5,366.65% (2024).
- Quarterly analysis of 5 years shows Cytokinetics' Debt to Equity stood at $0.19 in 2021, then tumbled by 409.04% to -$0.60 in 2022, then skyrocketed by 70.48% to -$0.18 in 2023, then slumped by 336.62% to -$0.77 in 2024, then skyrocketed by 95.55% to -$0.34 in 2025.
- Its last three reported values are -$0.34 in Q3 2025, -$0.48 for Q2 2025, and -$0.39 during Q1 2025.